Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.40 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1759521 | 0.85 | KEAP1 (0.61) | TBXAS1CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL11008025 | 0.85 | TBXAS1 (0.45) | TBXAS1CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL11011577 | 0.84 | ACHE (0.60) | TBXAS1CYP3A4CYP1A2ACHEEGLN3 | |
| SCHEMBL8699805 | 0.82 | ACHE (0.59) | TBXAS1CYP3A4CYP1A2ACHEEGLN3 | |
| SCHEMBL8510756 | 0.81 | TBXAS1 (0.50) | TBXAS1CYP3A4ACHEEGLN3KDM4E | |
| SCHEMBL4744809 | 0.81 | TBXAS1 (0.50) | TBXAS1ACHEEGLN3 | |
| Hydrochloric Acid SCHEMBL28306929 | 0.81 | ACHE (0.57) | TBXAS1CYP3A4CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL12780550 | 0.81 | TERT (0.48) | CYP3A4CYP2D6CYP2C19CYP1A2CYP2C9 | |
| SCHEMBL591937 | 0.79 | TBXAS1 (0.48) | TBXAS1CYP3A4CYP2D6ACHEEGLN3 | |
| SCHEMBL10294629 | 0.79 | TBXAS1 (0.50) | TBXAS1CYP3A4ACHEEGLN3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008005908-A2 | PYRIDOIMIDAZOLE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | WO | claimed |
| US-9878990-B2 | Benzylhydroxide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2018-01-30 | — | — | US | disclosed |
| US-20170313674-A1 | BENZYLHYDROXIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2017-11-02 | — | — | US | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| WO-2008005908-A2 | PYRIDOIMIDAZOLE DERIVATIVES | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2008-01-10 | — | — | WO | disclosed |
| EP-1268431-B1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH CORP (US) | 2007-08-29 | — | — | EP | disclosed |
| WO-2007054831-A2 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. (CA) | 2007-05-18 | — | — | WO | disclosed |
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | WYETH | 2004-09-09 | — | — | US | disclosed |
| US-6689772-B1 | ANTINEOPLASTIC AGENTS; OSTEOPOROSIS; POLYCYSTIC KIDNEY DISEASE; ANTIVIRAL AGENTS | WYETH | 2004-02-10 | — | — | US | disclosed |
| US-6521618-B2 | Antineoplastic agents, agents for treatment of osteoporosis and polycystic kidney disease | WYETH | 2003-02-18 | — | — | US | disclosed |
| EP-1268431-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-02-28 | — | — | US | disclosed |
| WO-2001072711-A1 | 3-CYANOQUINOLINES,3-CYANO-1,6-NAPHTHYRIDINES, AND 3-CYANO-1,7-NAPHTHYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2001-10-04 | — | — | WO | disclosed |
| US-4339448-A | Imidazole-copper complex compounds and fungicides containing them | BASF AKTIENGESELLSCHAFT (DE) | 1982-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176602-A1 | 3-Cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | TBXAS1 1060/4885CYP3A4 4137/4885CYP2D6 4078/4885 |
| US-20170313674-A1 | BENZYLHYDROXIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, CYP27A1 | TBXAS1 381/4885CYP3A4 109/4885CYP2D6 33/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | TBXAS1 2053/4885CYP3A4 4279/4885CYP2D6 4501/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | TBXAS1 2050/4885CYP3A4 4228/4885CYP2D6 4436/4885 |
| US-20020026052-A1 | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors | PKD1, PKD2, CSNK1A1 | TBXAS1 1060/4885CYP3A4 4137/4885CYP2D6 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.